Exploration of Immunology, Год журнала: 2024, Номер unknown, С. 577 - 615

Опубликована: Окт. 18, 2024

Complement is both evolutionary and scientifically old. It predates the adaptive immunity by some 600 million years was first described in 1905 Jules Bordet Paul Ehrlich. For most of its, existence complement system has been ignored scientists clinicians due to perception it being complicated its relevance for pathogenesis human disease unclear. With recent US Food Drug Administration (FDA) approvals pegcetacoplan paroxysmal nocturnal haemoglobinuria (PNH) geographic atrophy (GA), avacincaptad pegol GA iptacopan danicopan PNH, we are at a crucial juncture complement-targeting therapies. A number companies academic institutions developing next-generation therapies, which resulting an increasingly competitive landscape. If one looks serum cascade, all 3 pathways now have biotechnology or pharmaceutical industry players with 1 multiple clinical-stage inhibitors that expected be FDA approved within next few years. Furthermore, limited clinically validated targets complement-mediated disease, competition this space set further intensify coming In review, will discuss timeline discoveries led development current crop FDA-approved therapeutics. We follow discussion crowded therapy scientific advances emerged two decades underpinning future innovation, including our understanding biology, such as local intracellular complement, emerging targets, combinational approaches non-complement therapeutics unlock new indications technologies gene therapy. also give comprehensive overview landscape how can utilized target dysregulation.

Язык: Английский